Drug Type Small molecule drug |
Synonyms Novobiocin, Novobiocin (Varsity Pharmaceuticals), Novobiocin sodium (JAN/USP) + [2] |
Target |
Action inhibitors |
Mechanism POLQ inhibitors(DNA polymerase theta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date United States (04 Sep 1964), |
Regulation- |
Molecular FormulaC31H36N2NaO11 |
InChIKeyBZFOBLOAMAJKQV-RNROJPEYSA-N |
CAS Registry1476-53-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01209 | Novobiocin Sodium | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bacterial Infections | United States | 04 Sep 1964 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United Kingdom | 30 Jan 2022 |